Sun Pharmaceutical Industries, based in Mumbai, is poised to acquire Organon & Co., a New Jersey-based pharmaceutical company, for $12.5 billion, marking its most significant overseas acquisition to date. This deal involves a $4.5 billion equity purchase at a 53% premium over Organon's recent stock price, along with inheriting $8.5 billion of debt. The acquisition is expected to enhance Sun's women's health portfolio and biosimilars segment, which is crucial for its growth strategy. Analysts view this acquisition favorably, citing Sun's proven track record of efficiently managing acquired companies. The deal comes as Organon has seen its stock price surge by 81.29% in recent weeks amid acquisition speculation. Sun Pharma's executive chairman, Dilip Shanghvi, has emphasized the need for Indian pharmaceutical companies to pivot towards innovative research while maintaining their generics leadership. The acquisition is anticipated to be finalized soon, with a formal announcement expected shortly.